NCT00000633View on ClinicalTrials.gov

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 1998

Conditions
HIV Infections
Interventions
BIOLOGICAL

gp160 Vaccine (Immuno-AG)

BIOLOGICAL

Hepatitis B Vaccine (Recombinant)

Trial Locations (2)

21287

Johns Hopkins Adult AIDS CRS, Baltimore

63104

Washington U CRS, St Louis

Sponsors

Collaborators (1)

Immuno-US
All Listed Sponsors
collaborator

Immuno-US

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH